acrs stock: Aclaris Therapeutics Overview

ACRS (Aclaris Therapeutics, Inc.)

This article covers the company behind the ticker ACRS and the publicly traded stock commonly searched as "acrs stock". Aclaris Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused primarily on dermatology and immuno‑inflammatory therapeutics, together with a contract research services segment. This entry describes the business, clinical pipeline, corporate milestones, financial overview, public-market details for the ACRS stock, and practical guidance on where investors can find official, time-sensitive information.

As of 2026-01-29, according to Aclaris investor communications and public market pages, Aclaris remains listed on the Nasdaq exchange under the ticker ACRS. This article does not provide investment advice; it provides a structured, neutral primer so readers can better understand the company and the specific risks tied to clinical-stage biotech equities like acrs stock.

Quick summary / Lead

Aclaris Therapeutics (ticker: ACRS) is a clinical-stage biopharmaceutical company focused on dermatology and immuno-inflammatory diseases and operates a contract research business to complement its therapeutic R&D. The company's shares trade on Nasdaq; ACRS is typically classified in the micro- or small-cap range and can be subject to high volatility typical of clinical-stage biotech firms. This article summarizes the company's history, pipeline highlights, how to interpret financial and market data for acrs stock, and where to locate authoritative filings and updates.

Company background

Founding and corporate history

Aclaris Therapeutics was incorporated as a clinical-stage biopharma focused on dermatology and immuno-inflammatory conditions. The company built its reputation around targeted dermatology therapeutics and has evolved by advancing clinical programs, raising capital through private and public financings, and maintaining a dual focus on both therapeutics and contract research. Headquartered in the United States, Aclaris completed the steps required to list shares publicly on Nasdaq under the symbol ACRS. For precise founding dates, founder names, and incorporation details, consult the company’s SEC filings and the investor relations section of the corporate website.

Mission and business model

Aclaris states a mission to develop new medicines for dermatologic and immune-inflammatory diseases with unmet medical need. The company operates two complementary business lines:

• Drug discovery and clinical development: advancing small molecules and biologics through preclinical studies and human trials toward potential regulatory filings and commercialization.
• Contract research services: providing certain research and development services that diversify revenue streams and create operational synergies with the therapeutic pipeline.

Aclaris uses targeted R&D approaches and platform technologies to identify and optimize therapeutic candidates. Depending on company disclosures, these discovery engines may be referred to by internal names (for example, a platform or engine such as a kinase-targeting approach or other discovery module). When reviewing acrs stock, investors should identify specific R&D platforms named in official releases and read technical appendices in SEC filings or scientific presentations to understand how the company advances candidates from discovery to clinic.

Products and pipeline

Lead drug candidates and programs

Aclaris' pipeline historically focused on dermatology indications. Principal clinical programs have included candidates identified by internal development codes (examples such as ATI-052, ATI-2138, and other clinical-stage molecules cited by the company). Some pipeline items have targeted conditions such as alopecia areata, atopic dermatitis, pruritus, and other immune-mediated skin diseases. Trial phases for each candidate vary by program and may include Phase 1, Phase 2, or later-stage studies depending on progress.

Important notes when reading pipeline descriptions for acrs stock:

• Program names and codes: Always cross-check program codes (e.g., "ATI-052") against the company’s most recent pipeline slide deck or press release to confirm indication and phase.
• Trial endpoints and readout timelines: The impact on stock price for acrs stock tends to correlate strongly with trial readouts, primary endpoint achievement, and regulatory interactions.
• Mechanism of action and comparator landscape: Review scientific materials to see how a candidate’s mechanism differs from existing therapies and competing pipelines.

Contract research services

Aclaris has operated contract research or service offerings to provide R&D support and to diversify revenue. The contract research segment can include laboratory services, clinical-stage support, or other specialized capabilities aligned with dermatology and immunology. For acrs stock, this segment is notable because it can:

• provide non‑dilutive or lower-volatility revenue compared with pure clinical-stage R&D;
• extend the firm’s cash runway by contributing operating cash flow; and
• create operational leverage, as infrastructure for internal programs can be shared with external clients.

When evaluating acrs stock, check the latest revenue breakdown in the company’s 10-Q or 10-K to see how much contract research contributes to total revenue and trends quarter over quarter.

Key corporate events and milestones

A chronological list of highlights that matter for acrs stock typically includes:

• IPO / Nasdaq listing: date of listing and initial offering terms (shares and price) for ACRS.
• Major clinical trial readouts: announcements of trial initiation, top-line results, or termination decisions for lead candidates.
• Regulatory interactions: FDA meetings, clinical hold lifts, or other regulator communications that materially affect development timelines.
• Partnerships and collaborations: licensing deals, codevelopment agreements, or commercial partnerships that change the company’s risk profile or potential revenue streams.
• Index inclusions: inclusion in sector indices such as the Nasdaq Biotechnology Index can affect passive flows and liquidity for acrs stock.
• Financings and corporate transactions: registered direct offerings, PIPEs, convertible notes, stock-based acquisitions, or buybacks that change share count or capital structure.

For exact dates and the specifics of each milestone affecting acrs stock, consult the company’s press releases, Form 8‑K filings, and investor presentations. As of 2026-01-29, consult those primary sources for the latest milestone record.

Financial overview (company-level)

Below are the key financial categories and how to present them when analyzing acrs stock. Because Aclaris is clinical-stage, many readers will find operating losses and cash-balance trends more informative than traditional profitability metrics.

Recent financial performance

When summarizing recent performance for acrs stock, include:

• Revenue: total revenue and breakdown (e.g., contract research vs. milestones or product royalties if any).
• Net income (loss): operating loss and net loss attributable to the company.
• Cash flow from operations: trend in operating cash burn.
• Quarter-over-quarter and year-over-year trends: directionality is important for narrative around runway and funding needs.

Always cite the most recent 10‑Q or 10‑K and the quarter-end press release. Phrase such summaries with date specificity: "As of [quarter-end date], according to the company’s [10‑Q/press release], revenue was…, net loss was…, and cash on hand was…" to ensure the reader can verify the numbers.

Balance sheet and liquidity

For acrs stock, key balance sheet items to report are:

• Cash and cash equivalents: available liquidity to fund operations and trials.
• Short- and long-term debt: any convertible notes or credit facilities.
• Working capital and tangible assets: to understand near-term solvency.
• Runway estimates: calculated as cash on hand divided by monthly burn; state assumptions (e.g., burn rate used and whether collaborations or milestone payments are expected).

Because financings are common in clinical-stage biotechs, note any committed financing or shelf registration statements that could lead to share issuance. These items materially affect dilution expectations for acrs stock.

Profitability and valuation metrics

Standard valuation metrics like price-to-earnings (P/E) are often not meaningful for clinical-stage biotechs because earnings are negative. For acrs stock, more relevant ratios include:

• Enterprise value / revenue or price-to-sales (P/S) when revenue exists.
• Market capitalization and enterprise value.
• Cash per share and adjusted market cap excluding cash (useful to gauge implied value of pipeline).

A cautionary note: biotech valuation can be highly volatile and driven by binary clinical outcomes. Report valuation metrics with the date and data source: e.g., "Market cap as of [date] per Yahoo Finance / Nasdaq." Avoid presenting ratio results without the underlying numbers and the date they were pulled.

Stock market information (ACRS)

Trading details

• Ticker symbol: ACRS
• Primary exchange: Nasdaq
• Trading hours: Regular Nasdaq trading hours are 9:30 a.m. to 4:00 p.m. Eastern Time (pre-market and after-hours trading also occur outside those hours).
• Currency: U.S. dollars (USD)

When writing about acrs stock, state the exchange and currency explicitly and include the date when quoting prices or volumes.

Price history and metrics

Key items investors typically review for acrs stock include:

• Current price and historical price ranges (intraday, 1‑day, 1‑year, 52‑week high/low).
• Average daily trading volume and recent volume spikes, which may indicate heightened investor interest.
• Float and shares outstanding: free float can affect liquidity and volatility; shares outstanding affects per-share metrics and dilution calculations.

To report these figures accurately, cite a market data provider (for example, Nasdaq, Yahoo Finance, or the company’s investor page) and include the date of the quote.

Market capitalization and classification

ACRS is generally classified as a micro‑cap or small‑cap biotechnology company. Micro- and small-cap classification implies:

• Lower liquidity relative to large-cap stocks; larger bid-ask spreads.
• Greater susceptibility to large price moves from news, trial readouts, or analyst coverage changes.

When describing market capitalization for acrs stock, provide the date and source of the market-cap figure.

Dividends and corporate actions

Clinical-stage biotech companies rarely pay dividends. Historically, Aclaris has not had a dividend policy; investors in acrs stock primarily look for value through R&D progress, commercialization, or corporate transactions. Note any past stock splits, reverse splits, buybacks, or shareholder-authorized repurchase programs if they exist; reference the date and SEC filings.

Recent stock performance and technical/market drivers

Short-term price action for acrs stock is typically driven by:

• Clinical trial news: initiation, enrollment updates, interim results, and top-line readouts.
• Regulatory milestones: FDA meetings, clinical holds lifted, or approvals.
• Financing events: registered offerings, debt agreements, or equity sales that affect share count and perceived dilution.
• Partnerships and licensing: announcements of collaborations with larger pharma or biotech firms.
• Broader biotech sector trends: movements in the Nasdaq Biotechnology Index or healthcare ETFs can influence sentiment around acrs stock.

Volume spikes often accompany press releases or analyst notes. For readers tracking acrs stock, add alerts for company press releases, Form 8‑Ks, and scheduled investor events where new data may be revealed.

Analysts, ratings and investor sentiment

Analyst coverage and consensus ratings

Coverage of acrs stock can be limited compared with large-cap names. When analysts do cover the company, they often publish initiation reports, research notes after trial readouts, or updated price targets following major news.

To summarize analyst sentiment for acrs stock, include:

• Which sell-side firms provide coverage (name the firms in your summary and cite the reports).
• Consensus rating and range of price targets, with dates and sources for each target.
• Note that analyst coverage can be sparse; absence of coverage can increase retail-driven volatility.

Retail / social sentiment

Retail interest in acrs stock can be tracked through volume trends, social platforms such as StockTwits, and message-board activity. High retail participation can magnify volatility and quicken price moves unrelated to fundamentals. When reporting social sentiment, cite activity spikes (dates and platforms) and remind readers that social signals are noisy and not a substitute for primary filings.

Ownership and insider activity

For acrs stock, key ownership and activity items include:

• Major institutional holders and their reported percentage ownership.
• Insider holdings by executives and board members.
• Recent insider transactions (open-market purchases or sales) reported via Form 4 filings.
• Short interest and days-to-cover metrics, which may inform potential short-squeeze dynamics or negative sentiment.

When summarizing ownership for acrs stock, use the latest publicly filed 13F reports for institutional holdings, and Form 4/13D/G filings for insider and activist disclosures. Always provide the date of the data extract.

Risks and considerations for investors

Investing in acrs stock carries multiple risks typical of clinical-stage biotech companies. Below are the principal categories to consider.

Clinical and regulatory risk

• Trial failure risk: Clinical programs are binary in many respects—a failed primary endpoint often materially reduces clinical value.
• Regulatory uncertainty: FDA feedback, requests for additional data, or changes in guidance can extend timelines or alter approval prospects.
• Enrollment and execution risk: Delays or difficulties enrolling trials can push timelines and increase cash burn.

These risks are central to acrs stock valuation; read trial protocols, statistical analysis plans, and safety updates to properly contextualize announcements.

Financial and liquidity risk

• Cash runway and dilution: Clinical-stage firms often need to raise capital. If cash is insufficient to reach value-enhancing inflection points, the company may issue equity or raise debt, diluting existing shareholders.
• Market liquidity: ACRS’s classification as a micro- or small-cap can mean wider bid-ask spreads and larger price impact when placing trades.

Investors should calculate runway based on disclosed cash and burn rate, and monitor for announced financings or shelf registration statements.

Market and operational risk

• Competitive landscape: Other companies may develop superior therapies or gain first-mover advantage in target indications.
• Intellectual property and patent risk: Weak IP protection limits exclusive commercialization potential.
• Dependence on a small pipeline: A small number of clinical programs increases the company’s concentration risk—one negative readout can disproportionately affect acrs stock.

Corporate governance and management

When evaluating acrs stock, review the company’s leadership and board composition:

• Executive team: CEO, CFO, chief medical officer, and heads of R&D—short bios and previous experience in drug development matter.
• Board oversight: Board independence, committee structure, and prior board experience in biotech and corporate finance.
• Governance events: Any recent changes in leadership, special committee formations, or shareholder proposals that materially alter strategy or oversight.

Good governance signals can reduce operational risk and provide more predictable capital allocation decisions, which investors in acrs stock should monitor.

Investor relations and primary sources of information

For accurate, timely information about acrs stock, always consult primary official sources. These include:

• Company investor relations page and press releases (often labeled by date and topic).
• SEC filings: 10‑Q (quarterly report), 10‑K (annual report), 8‑K (current reports for material events), Form 4 (insider trades), and proxy statements.
• Exchange disclosures on Nasdaq’s company page for ticker ACRS.
• Major market-data providers for price, volume, market cap, and historical charts (e.g., Yahoo Finance, Morningstar, CNBC).
• Social and retail platforms for sentiment indicators, but treat these as supplemental to primary filings.

As of 2026-01-29, according to the company investor-relations materials and filings, readers should confirm the most recent cash balance, revenue, and trial-readout timelines via the company’s latest 8‑K, 10‑Q, or investor presentation. Always note the date of each cited figure.

When you want to trade or store assets related to crypto or use a trading venue that supports equities and derivatives, consider using Bitget. Bitget provides trading products and custodial options; for wallet needs, Bitget Wallet is recommended in this article. (This is a platform suggestion, not an investment recommendation.)

See also

• Nasdaq Biotechnology Index (as a sector benchmark)
• Peers and comparators in dermatology and immuno-inflammatory biotech
• Common biotech financial metrics glossary (burn rate, runway, top-line readout, primary endpoint)

References and data sources

The following primary sources are recommended when compiling or updating any facts, numeric data, or time-sensitive metrics for acrs stock:

• Company investor relations materials and press releases (Aclaris investor relations). As of 2026-01-29, refer to the latest press releases and presentation decks.
• SEC filings: 10‑K (annual), 10‑Q (quarterly), 8‑K (material events), Form 4 (insider trades).
• Nasdaq company page for ACRS for official exchange and listing details.
• Market-data providers for price and volume: Yahoo Finance (ACRS quote page), Morningstar profile, CNBC or CNN Markets quote pages.
• Analyst research platforms such as Zacks or other sell-side reports for consensus ratings and target ranges.
• Social and retail-sentiment platforms: StockTwits feed for ACRS.

When including numeric facts (market cap, price, volume, cash balances), always cite the exact source and the date of the data point. Example phrasing: "As of 2026-01-29, according to Yahoo Finance, ACRS had a market capitalization of [value]." Replace bracketed numbers with the latest figures from the cited provider.

Notes on scope and maintenance

• Time-sensitive numeric data: Prices, market cap, analyst targets, and short interest change frequently. Update these items at each article refresh and include the source and "as of" date.
• Clinical status: Pipeline statuses and trial phases must be verified against the latest press releases, clinicaltrials.gov entries, and SEC filings.
• Neutral tone: This article is informational and avoids investment advice. Readers should consult professional advisors and primary filings before making investment decisions related to acrs stock.

Practical checklist for updating an article about acrs stock

1. Pull the latest 10‑Q/10‑K and most recent 8‑Ks; update cash, revenue, and net loss figures with dates.
2. Update market data: latest share price, 52‑week high/low, average volume, float, and market cap with source and as‑of timestamp.
3. Confirm pipeline changes and trial readouts using the company’s press releases and clinicaltrials.gov listings.
4. Check for recent financings or equity issuances and note potential dilution.
5. Refresh analyst coverage and any new price targets or initiations.
6. Review insider filings (Form 4) and institutional 13F holdings for material ownership changes.
7. Re-check governance updates and executive changes; cite proxy statements or Form 8‑K.
8. Add a dated "What’s new" summary at the top for rapid reader consumption.

Final notes and how to act next

This article provides a structured primer on Aclaris Therapeutics and the publicly traded acrs stock to help beginners and informed readers navigate company and market details. For tradable exposure, consider market liquidity and platform features—Bitget is available for traders seeking access to a range of trading products. For custody and wallet needs, Bitget Wallet is recommended.

To stay current: subscribe to the company’s investor mailing list, set alerts for Aclaris press releases and SEC filings, and check market-data pages for daily price and volume movements. Always verify quantitative metrics with the original filings and exchange quotes before making trading decisions.

Further exploration: consult the sources listed above and the company’s latest investor presentation.